CeriBell (NASDAQ:CBLL) Releases Earnings Results, Beats Estimates By $0.02 EPS

Key Points

• CeriBell (NASDAQ:CBLL) reported quarterly earnings of ($0.38) per share, beating estimates by $0.02.
• The company updated its fiscal year 2025 guidance and has a consensus price target of $32.14, with eight analysts rating the stock as a "buy."
• Insiders sold a total of 113,633 shares in the last quarter, with notable sales from Director Rebecca B. Robertson and CEO Xingjuan Chao.

CeriBell (NASDAQ:CBLL - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02, Zacks reports. CeriBell had a negative return on equity of 48.42% and a negative net margin of 63.83%. The firm had revenue of $21.20 million during the quarter, compared to analyst estimates of $20.52 million. CeriBell updated its FY 2025 guidance to EPS.

CeriBell Stock Performance

CeriBell stock traded up $0.33 during mid-day trading on Friday, hitting $12.91. 629,190 shares of the company's stock traded hands, compared to its average volume of 289,622. The firm has a 50 day moving average price of $16.70 and a 200 day moving average price of $18.54. The company has a quick ratio of 16.81, a current ratio of 13.31 and a debt-to-equity ratio of 0.11. The company has a market cap of $473.28 million and a PE ratio of -4.32. CeriBell has a one year low of $10.01 and a one year high of $32.75.

Wall Street Analysts Forecast Growth

Separately, BTIG Research initiated coverage on CeriBell in a report on Tuesday, June 24th. They set a "buy" rating and a $30.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell has an average rating of "Buy" and a consensus price target of $32.14.

Insider Buying and Selling at CeriBell

In other CeriBell news, Director Rebecca B. Robertson sold 11,188 shares of CeriBell stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $17.85, for a total transaction of $199,705.80. Following the sale, the director owned 10,042 shares of the company's stock, valued at $179,249.70. The trade was a 52.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Xingjuan Chao sold 25,000 shares of CeriBell stock in a transaction on Monday, July 7th. The shares were sold at an average price of $17.70, for a total value of $442,500.00. Following the sale, the chief executive officer directly owned 776,022 shares in the company, valued at $13,735,589.40. The trade was a 3.12% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 113,633 shares of company stock worth $1,965,261 in the last ninety days. 20.10% of the stock is owned by company insiders.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.